p140 peptide P140 Peptide - P140 peptidefor lupus P140 The Therapeutic Potential of the P140 Peptide in Autoimmune Diseases

P140 peptidefor lupus The p140 peptide is emerging as a significant therapeutic agent with the potential to revolutionize the treatment of autoimmune and inflammatory diseases.作者：N Page·2009·被引用次数：81—Here we show thatP140 peptidebinds a unique cell-surface receptor, the constitutively-expressed chaperone HSC70 protein, known as a presenting-protein. P140 induces apoptosis of activated MRL/lpr CD4+T cells. In P140-treated mice, it increases peripheral blood lymphocyte apoptosis and decreases B ... This synthetic peptide is derived from the spliceosomal protein U1-70K, specifically a 21-mer sequence (131-151) that has been chemically modified to include a phosphoserine residue at position 140.P140 Peptide Leads to Clearance of Autoreactive ... - Frontiers This modification is crucial to its function, giving rise to the unique properties of the P140 peptide. The P140 peptide, also known by its investigational drug names Lupuzor™ and forigerimod, is being developed as a first-in-class therapy targeting the root causes of conditions like systemic lupus erythematosus (SLE).

Research indicates that the P140 peptide functions by modulating the immune system, specifically by targeting autoreactive T and B cells. Data suggests that P140 acts by depleting hyper-activated autoreactive lymphocytes, thereby restoring a normal immune homeostasisAutophagy pathway as a target of therapeutic P140 peptide .... This immunomodulatory action is a significant departure from traditional treatments that often suppress the entire immune system, leading to a range of side effects. Instead, the P140 peptide aims to re-educate the immune system, promoting tolerance rather than broad suppression.

A key mechanism of action for the P140 peptide involves its interaction with the chaperone protein HSPA8/HSC70. Studies have shown that P140 peptide binds to this constitutively-expressed chaperone protein, which acts as a presenting protein.作者：R Zimmer·2013·被引用次数：200—A longer treatment period appears necessary to increase the number of responders. Thepeptide P140/Lupuzor is a promiscuous MHC class II binder that is ... This binding is believed to trigger downstream effects that lead to the apoptosis of activated autoreactive CD4+ T cells.Effect of P140 peptide on the expression of ATG5-ATG12 ... In preclinical models, treatment with P140 has been observed to increase peripheral blood lymphocyte apoptosis and decrease the recognition of autoepitopes by T cells. Furthermore, findings suggest that P140 down-regulates HLA class II overexpression in human lupus B cells and hampers their function, indicating a broad impact on autoimmune cell activity.P140is a 21-merpeptide(sequence 131-151, phosphorylated at position 140) that is derived from the spliceosomal protein U1-70K.

The efficacy and safety of the P140 peptide have been investigated in clinical trials, particularly for patients with systemic lupus erythematosus (SLE).作者：N Schall·2012·被引用次数：64—▻ The phosphopeptideP140improves the clinical and biological features of lupus mice. ▻P140influences the autophagic flux in APCs and destabilizes MHC ... A randomized, double-blind, placebo-controlled phase IIb clinical trial, for example, evaluated the P140 peptide in patients with SLE. The results indicated that the peptide P140 improved clinical and biological features of lupus.Emerging Use of BPC-157 in Orthopaedic Sports Medicine - PMC In one study, Lupuzor/P140 peptide given at a dose of 200 µg three times at 4-week intervals over 12 weeks, in addition to standard of care, was found to be efficacious and generally well-tolerated. This suggests that a longer treatment period may be necessary to maximize the number of responders. The P140 peptide is recognized by lupus CD4+ T cells and has been studied for its safety, tolerability, and efficacy in treating SLEThe therapeutic P140 peptide, a new immunomodulating ....

Beyond its direct impact on T and B cells, the P140 peptide also influences other cellular processes implicated in autoimmune diseases. Research points to the P140 peptide influencing the autophagic flux in antigen-presenting cells (APCs) and destabilizing MHC molecules.Chaperone-Mediated Autophagy As a Target Of ... Additionally, data suggests that the P140 may restore tolerance by acting as an altered peptide ligand of the T cell receptor and reduces the autophagic process, which has been linked to autoimmune pathogenesis. Studies have also explored the effect of peptide P140 on inflammatory responses in various cell and animal models, including crystal-induced gout.P140(Lupuzor™, forigerimod) is a first-in-classpeptide-based therapy designed to address the root cause of autoimmune and inflammatory diseases.

The development of the P140 peptide represents a significant advancement in the field of immunomodulation作者：N Page·2009·被引用次数：81—Here we show thatP140 peptidebinds a unique cell-surface receptor, the constitutively-expressed chaperone HSC70 protein, known as a presenting-protein. P140 induces apoptosis of activated MRL/lpr CD4+T cells. In P140-treated mice, it increases peripheral blood lymphocyte apoptosis and decreases B .... Its ability to target specific autoreactive cells while potentially preserving essential immune functions offers a promising therapeutic avenue for patients suffering from debilitating autoimmune conditions. The ongoing research into the P140 peptide and its mechanisms of action continues to shed light on its broad therapeutic potential.

Entities and LSI keywords extracted:

* P140 peptide

* peptide

* P140

* Lupuzor™

* forigerimod

* U1-70K protein

* phosphoserine residue

* autoreactive T cells

* autoreactive B cells

* immune homeostasis

* HSPA8/HSC70 chaperone protein

* apoptosis

* CD4+ T cells

* systemic lupus erythematosus (SLE)

* HLA class II

* antigen-presenting cells (APCs)

* MHC molecules

* T cell receptor

* autophagic flux

* autophagy

* immunomodulation

* autoimmune diseases

* inflammatory diseases

* splenocyte apoptosis

* autoepitope recognition

* B cell function

* promiscuous MHC class II binder

* spliceosomal protein

* chaperone-mediated autophagy

* autophagy pathway

* ATG5-ATG12

* crystal-induced gout

* rheumatoid arthritis

* Sjögren's syndrome

* polyarthritis

* p140 Cap peptide

* Anti-p140Cap Antibody

* SRCIN1 blocking peptide

* CeSPIACE

* COVID-19 variants

* orthopaedic sports medicine

* BPC-157

* ImmuPharma PLC

* CEP 33457

* IPP 201101

* 497156-60-2

* Lupuzor/200 µg

* standard of care (SOC)

* physicochemical properties

* solubility limit

* distilled water

* phosphate-buffered saline (PBS)

* RPMI 1640 culture medium

* mannitol 5.4%

* ALW peptide